Immunoreactivity in lung cancer.
Lung cancer has been associated with suppression of the cellular immune system. Recent experimental evidence suggests that recognition of HLA class I molecules by cytolytic T lymphocytes is important for tumor resistance. Augmentation of this interaction may soon play a role in cancer therapy.
Mentzer
S J
SJ
Division of Thoracic Surgery, Brigham and Women's Hospital, Boston, Massachusetts, USA.
D000276:Adjuvants, Immunologic / Q000008:administration & dosage; D000818:Animals; D000942:Antigens, Bacterial / Q000276:immunology; D002986:Clinical Trials as Topic; D004653:Empyema / Q000276:immunology; D005805:Genes, MHC Class I / Q000276:immunology; D006680:HLA Antigens / Q000276:immunology; D000882:Haplorhini; D006801:Humans; D007694:Killer Cells, Natural / Q000276:immunology; D008175:Lung Neoplasms / Q000276:immunology* / Q000401:mortality; D008214:Lymphocytes / Q000276:immunology; D051379:Mice; D009365:Neoplasm Regression, Spontaneous / Q000276:immunology; D013045:Species Specificity; D013601:T-Lymphocytes / Q000276:immunology; D014407:Tumor Cells, Cultured / Q000276:immunology
D000276:Adjuvants, Immunologic; D000942:Antigens, Bacterial; D006680:HLA Antigens